New Translational Imaging Center Opens
MPI Research, inviCRO, and 3D Imaging open its new Translational Imaging Center in Michigan.
MPI Research, inviCRO, and 3D Imaging, have opened its new Translational Imaging Center at the global headquarters of MPI Research in Mattawan, Mich. The facility will be used to accelerate pharmaceutical discovery and development of new and improved therapeutics. The 10,000 sq ft, two-story facility features the first commercially available cyclotron (pictured at left), which provides new opportunities for scientists to accelerate the drug development process through the utilization of radioisotopes in molecular imaging to track distribution and efficacy of drug candidates.
The partnership between MPI Research, inviCRO, and 3D Imaging offers a combination of translational equipment and expertise to generate the images and data sets needed to enhance drug development decisions. MPI Research provides contract research services, while inviCRO provides a range of imaging services and software solutions. 3D Imaging operates the cyclotron, bringing new radiochemistry to drug development research.
The three organizations began the project in September 2013, and the cyclotron arrived in February 2014.
Source: MPI Research
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
